- Home
- PULM vs GBIO Comparison
PULM vs GBIO Comparison
Compare PULM & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- GBIO
- Stock Information
- Founded
- PULM 2003
- GBIO 2016
- Country
- PULM United States
- GBIO United States
- Employees
- PULM N/A
- GBIO N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- GBIO Health Care
- Exchange
- PULM Nasdaq
- GBIO Nasdaq
- Market Cap
- PULM 33.2M
- GBIO 29.2M
- IPO Year
- PULM N/A
- GBIO 2020
- Fundamental
- Price
- PULM $6.41
- GBIO $0.52
- Analyst Decision
- PULM
- GBIO Strong Buy
- Analyst Count
- PULM 0
- GBIO 4
- Target Price
- PULM N/A
- GBIO $7.33
- AVG Volume (30 Days)
- PULM 57.7K
- GBIO 1.8M
- Earning Date
- PULM 08-12-2025
- GBIO 08-06-2025
- Dividend Yield
- PULM N/A
- GBIO N/A
- EPS Growth
- PULM N/A
- GBIO N/A
- EPS
- PULM N/A
- GBIO N/A
- Revenue
- PULM $1,921,000.00
- GBIO $24,556,000.00
- Revenue This Year
- PULM N/A
- GBIO N/A
- Revenue Next Year
- PULM $134.88
- GBIO N/A
- P/E Ratio
- PULM N/A
- GBIO N/A
- Revenue Growth
- PULM N/A
- GBIO 146.47
- 52 Week Low
- PULM $1.78
- GBIO $0.30
- 52 Week High
- PULM $10.40
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- PULM 37.18
- GBIO 66.42
- Support Level
- PULM $6.28
- GBIO $0.32
- Resistance Level
- PULM $6.83
- GBIO $0.59
- Average True Range (ATR)
- PULM 0.35
- GBIO 0.05
- MACD
- PULM -0.07
- GBIO 0.02
- Stochastic Oscillator
- PULM 0.00
- GBIO 76.34
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.